No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Idecabtagene vicleucel demonstrates higher efficacy over currently available therapies in triple-class relapsed and refractory multiple myeloma

byKathleen Lau

July 1, 2021

in StudyGraphics

Epidemiologic analysis of chilblains cohorts before and during the COVID-19 pandemic

RelatedReports

Development of a risk index for colorectal cancer screening

Gastroenterology

Structured exercise intervention improves survival in colon cancer patients

July 9, 2025

Pharma

2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]

July 8, 2025

Primary thromboembolism prophylaxis may be effective in advanced cancer

Hematology

AAV gene therapy shows durable benefit in hemophilia B

July 7, 2025

Lessons from real-world implementation of lung cancer screening

Oncology

Tumor-infiltrating clonal hematopoiesis is associated with NSCLC recurrence

July 7, 2025

Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation

Wellness Check: Sleep

Pediatric DKA associated with recent acute care visits

Sodium-glucose cotransporter 2 inhibitors associated with reduced mortality compared with sulfonylureas in patients with type 2 diabetes

$The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor$

Isatuximab improves progression-free survival in patients receiving carfilzomib–dexamethasone treatment for multiple myeloma

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports